Wyeth ReFacto Launch Set For Third Quarter; Awaiting Adequate Supply
Executive Summary
Wyeth-Ayerst is awaiting the production of commercial quantities of its antihemophilic factor ReFacto for introduction into the U.S. market.
You may also be interested in...
Wyeth Closes ReFacto And Premarin Facilities, Cites Low Demand As Reason
Wyeth is closing its ReFacto manufacturing plant in St. Louis due to lower demand for the antihemophilic Factor VIII product
Wyeth Closes ReFacto And Premarin Facilities, Cites Low Demand As Reason
Wyeth is closing its ReFacto manufacturing plant in St. Louis due to lower demand for the antihemophilic Factor VIII product
Wyeth To File Refacto AF Second Quarter; Will Launch End Supply Problems?
Wyeth plans to file its second-generation antihemophilic factor VIII product Refacto AF during the second quarter, Wyeth President-Global Pharmaceuticals Bernard Poussot said during a Jan. 28 analyst call